Lantheus and Fujifilm RI Pharma extend SPECT agent deal

Lantheus Medical Imaging has entered into a new agreement with Fujifilm RI Pharma (FRI) to license and distribute Cardiolite and Neurolite imaging agents in Japan.

The 10-year agreement, effective Jan. 1, immediately follows an earlier 10-year agreement between North Billerica, Mass.-based Lantheus and FRI. Lantheus will continue to supply FRI with the agents in finished form, as well as provide the raw materials to manufacture and sell the products in unit dose form.

Cardiolite and Neurolite are technetium-based radiopharmaceutical imaging agents used in SPECT imaging.